11:38 AM EST - Theralase Technologies Inc. : Has submitted a Clinical Trial Application for its anti-cancer technology to Health Canada for approval. Theralase’s anti-cancer technology utilizes the proprietary Theralase TLC-3200 Oncology Laser System to activate the Company’s lead Photo Dynamic Compound, TLD-1433, to treat Non-Muscle Invasive Bladder Cancer. Theralase Technologies Inc.
shares V.TLT are trading up $0.025 at $0.36.
